Core Viewpoint - The approval of Datroway, a TROP2-targeted antibody-drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca, marks a significant advancement in the treatment of HR-positive, HER2-negative breast cancer in China, addressing a critical need in the oncology market [1][1][1] Group 1: Product Approval - Datroway has received approval from the National Medical Products Administration (NMPA) in China for treating adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy [1][1][1] - This drug is the second ADC utilizing Daiichi Sankyo's proprietary DXd technology to be approved in China, highlighting the company's innovative capabilities in drug development [1][1][1] Group 2: Market Context - Breast cancer is the second most common malignant tumor among women in China, with approximately 357,000 new cases and 75,000 deaths reported in 2022, indicating a significant public health concern [1][1][1] - About 70% of diagnosed breast cancer cases are classified as HR-positive and HER2-negative, which underscores the importance of targeted therapies like Datroway in addressing this patient population [1][1][1]
达卓优 在华获批用于既往接受过治疗的HR阳性、HER2阴性转移性乳腺癌患者
Jing Ji Guan Cha Wang·2025-08-24 01:13